Drug Pricing | List of Frontiers open access articles

Original Research

Published on 10 May 2024

Are Turkish pharmaceutical pricing strategies an access barrier to oncology medicines for Türkiye?

in Drugs Outcomes Research and Policies

Elif Hilal Vural
Tolga Kaskati
İsmail Mert Vural
Mustafa Asım Özalp
Bülent Gümüşel

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1364341

4,498 views
5 citations

Original Research

Published on 22 Jan 2025

Drivers of innovation value: simulation for new drug pricing evaluation based on system dynamics modelling

in Drugs Outcomes Research and Policies

Qian Xing
Wendi Cheng
Wei Wang
Chunlin Jin
Haiyin Wang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1474856

3,203 views
2 citations

Original Research

Published on 07 Dec 2020

Drug Utilization and Drug Pricing in the Private Primary Healthcare System in Malaysia: An Employer Price Control Mechanism

in Health Economics

Che Suraya Zin
Nor Hidayah Taufek
Siti Halimah Bux

Frontiers in Public Health

doi 10.3389/fpubh.2020.551328

14,777 views
6 citations

Original Research

Published on 02 Sep 2025

Determinants of orphan drug health technology assessment in South Korea: an empirical analysis

in Drugs Outcomes Research and Policies

Se Hee Lee
Sung Kyung Lee
Jong Hyuk Lee
Joon Seok Bang

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1619984

2,220 views

Original Research

Published on 07 Jan 2025

Analysis of drug pricing drivers under South Korea’s pharmaco-economic evaluation exemption policy (2015–2022)

in Drugs Outcomes Research and Policies

Seung Rae Yu
Jong Hyuk Lee

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1519491

3,211 views
3 citations

Original Research

Published on 11 Jun 2025

China's coordinated tripartite medical reform: strategic balancing of interests among pharmaceuticals, healthcare, and health insurance

in Health Economics

Hanxiang Gong
Wenbo Wu
Jifeng Li
Baoling Wu
Mengqi Gao
Yajun Yang

Frontiers in Public Health

doi 10.3389/fpubh.2025.1591358

3,624 views
3 citations

Perspective

Published on 23 Dec 2020

Development and Use of Gene Therapy Orphan Drugs—Ethical Needs for a Broader Cooperation Between the Pharmaceutical Industry and Society

in Regulatory Science

Sandor Kerpel-Fronius
Varvara Baroutsou
Sander Becker
Roberto Carlesi
Luis Collia
Brigitte Franke-Bray
Peter Kleist
Chieko Kurihara
Luis Filipe Laranjeira
Kotone Matsuyama

Frontiers in Medicine

doi 10.3389/fmed.2020.608249

14,040 views
22 citations

Original Research

Published on 11 Aug 2025

Multinational cost-effectiveness analysis of pembrolizumab combined with chemotherapy as first-line treatment for advanced biliary tract cancer

in Health Economics

Yuxuan Xie
Quanyi Liu
Shanrui Xiao
Xia Li
Lin Qiu
Yun Gu

Frontiers in Public Health

doi 10.3389/fpubh.2025.1597550

2,840 views

Original Research

Published on 14 Oct 2025

Cost-effectiveness of cadonilimab plus chemotherapy vs chemotherapy alone for advanced gastric cancer: evidence to inform drug pricing in the U.S. and China

in Cancer Immunity and Immunotherapy

Wenwang Lang
Liuyong Mei
Qiang Xiao
Zujin Zhou
Huiqing Jiang
Xianling Zhao

Frontiers in Immunology

doi 10.3389/fimmu.2025.1618726

1,976 views

Original Research

Published on 09 Jun 2025

Adoptive cellular immunotherapy combined with chemotherapy versus chemotherapy alone in Chinese patients with metastatic colorectal cancer: a cost-effectiveness analysis to inform drug pricing

in Gastrointestinal Cancers: Colorectal Cancer

Liman Huo
Ping Liang
Yangyang Duan
Yanmei Xu
Jianhua Tang
Qi Lv
Rui Feng

Frontiers in Oncology

doi 10.3389/fonc.2025.1590319

2,567 views
1 citation

Original Research

Published on 26 Nov 2025

Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial

in Drugs Outcomes Research and Policies

Xiaohu Jin
Zhifeng Li

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1700291

1,120 views

Review

Published on 08 Dec 2025

Cost-effectiveness analysis of commercial Chinese polyherbal preparations for primary insomnia: based on network meta-analysis

in Ethnopharmacology

Sihong Yang
Fanya Yu
Xinghua Xiang
Chuchuan Wan
Yumeng Tan
Ning Ma
Yajing Li
Long Ge
Xing Liao
Hui Zhao

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1682173

1,150 views

Original Research

Published on 20 Jul 2023

Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing

in Drugs Outcomes Research and Policies

Yena Gan
Fenghao Shi
He Zhu
Sheng Han
Duoduo Li

Frontiers in Pharmacology

doi 10.3389/fphar.2023.1241130

4,934 views
7 citations

Review

Published on 05 Nov 2025

Durvalumab consolidation therapy in patients with stage III small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis

in Cancer Immunity and Immunotherapy

Hui Zhang
Yuhang Liu
Bikun Cai
Mengyi Wang
Haonan Li
Hong Wang

Frontiers in Oncology

doi 10.3389/fonc.2025.1643022

2,107 views

Articles

Are Turkish pharmaceutical pricing strategies an access barrier to oncology medicines for Türkiye?

Drivers of innovation value: simulation for new drug pricing evaluation based on system dynamics modelling

Drug Utilization and Drug Pricing in the Private Primary Healthcare System in Malaysia: An Employer Price Control Mechanism

Determinants of orphan drug health technology assessment in South Korea: an empirical analysis

Analysis of drug pricing drivers under South Korea’s pharmaco-economic evaluation exemption policy (2015–2022)

China's coordinated tripartite medical reform: strategic balancing of interests among pharmaceuticals, healthcare, and health insurance

Development and Use of Gene Therapy Orphan Drugs—Ethical Needs for a Broader Cooperation Between the Pharmaceutical Industry and Society

Multinational cost-effectiveness analysis of pembrolizumab combined with chemotherapy as first-line treatment for advanced biliary tract cancer

Cost-effectiveness of cadonilimab plus chemotherapy vs chemotherapy alone for advanced gastric cancer: evidence to inform drug pricing in the U.S. and China

Adoptive cellular immunotherapy combined with chemotherapy versus chemotherapy alone in Chinese patients with metastatic colorectal cancer: a cost-effectiveness analysis to inform drug pricing

Cost-effectiveness analysis of first-line versus second-line use of CDK4/6 inhibitors combined with endocrine therapy in advanced HR+/HER2- breast cancer in China: based on the SONIA trial

Cost-effectiveness analysis of commercial Chinese polyherbal preparations for primary insomnia: based on network meta-analysis

Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing

Durvalumab consolidation therapy in patients with stage III small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis